Ad-ucation? Sorvinos plug Lantus in Sanofi web effort

Share this article:
Ad-ucation? Sorvinos plug Lantus in Sanofi web effort
Ad-ucation? Sorvinos plug Lantus in Sanofi web effort
Sanofi Aventis launched a Lantus-branded “diabetes awareness campaign" featuring Paul and Mira Sorvino.

The father-daughter acting duo, he of Goodfellas fame and she of Mighty Aphrodite, feature in the Diabetes Co-Stars campaign, talking about Paul's type 2 diabetes, diagnosed in 2006. A video-rich microsite housed alongside Lantus- and Apidra-branded content, includes a "Resources" tab featuring a pile of links where readers can “find more information about Lantus insulin, the Lantus SoloStar pen, and downloadable tools to help you monitor your blood sugar.” Sorvino takes Lantus.

In one of the clips, Mira Sorvino recalls a worrying spell of high blood sugar her father suffered shortly after his diagnosis.

“So, at that point I realized that I, I needed to be a, uh, a better support to him and figure out what I could do to help him manage his blood sugars better and find out more about the disease,” says Sorvino. “I did speak with a doctor, I spoke with some experts, I had a friend who has diabetes…and I did some reading on the web. So, it's sort of a combination of informed sources, to help me understand it.”

“The information is there,” says her father. “You talk to professionals. A lot of it's on the web all you have to do is punch that up and visit those sites and you need to learn what it is that's happened to you.”

The site was executed by Euro RSCG Life 4D.

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.